Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that pigmented vellus and upright regrowing hairs are the only predictive trichoscopic markers of hair regrowth in patients with alopecia totalis and universalis.

In this prospective cohort, baseline severity, disease activity, and relapse history were identified as key factors influencing response and recurrence in alopecia areata, suggesting that implementing standardized assessments could enhance risk stratification and personalized care approaches.

This study found that patients with alopecia areata showing low treatment burden responded better to baricitinib compared to those with higher previous systemic treatment exposure.

In this study, low-dose oral minoxidil was found to have a favorable safety profile for treating alopecia, with mostly mild side effects, in both general and hypertensive populations.

In this phase 2 study, baricitinib at 2 mg and 4 mg doses significantly improved hair regrowth in adults with alopecia areata and ≥50% scalp hair loss compared to placebo, without new safety concerns, although the small sample size limits the results' generalizability.

This study found that 1% anthralin ointment effectively promoted hair growth in children with chronic, severe alopecia areata, showing complete or partial responses in 70% of participants over 12 months, without serious adverse events.

In this retrospective analysis, combination therapy with tofacitinib and oral minoxidil led to significant scalp hair regrowth in patients with severe alopecia areata, with 67% achieving at least 75% regrowth, although the small sample size limits the findings.

This study reviewed the literature on low-dose oral minoxidil as a primary treatment for various hair loss disorders, concluding that it is a successful and well-tolerated alternative to topical minoxidil for patients with poor adherence to other therapies.

This study observed that dupilumab led to significant hair regrowth and was well-tolerated in children with both alopecia areata and atopic dermatitis, showing promise as a safe treatment option for pediatric patients with associated atopy.

This review concluded that baricitinib and other oral JAK inhibitors have the most robust evidence supporting their use in treating severe alopecia areata in adults, compared to other less-evaluated treatments.

This review discusses the role of immune cells in the pathogenesis of alopecia areata and highlights emerging immunomodulatory strategies and novel therapeutic targets aimed at offering more effective and durable treatments for this autoimmune hair loss disorder.

This consensus statement outlines a treatment algorithm for alopecia areata, discussing when to consider systemic treatment and how to assess outcomes, without providing new clinical results.

This review found that JAK/STAT pathway inhibitors, such as tofacitinib and ruxolitinib, led to symptom improvement in all observed atopic dermatitis cases, but responses were mixed for vitiligo and alopecia areata, with a generally mild safety profile reported.

This study found that tofacitinib shows reasonable effectiveness for treating alopecia areata with mild adverse effects, although more large-scale randomized trials are needed to fully assess its safety and efficacy.

In this study, tofacitinib monotherapy was effective in achieving hair regrowth in over half of Korean patients with moderate-to-severe and refractory alopecia areata, though treatment discontinuation typically led to hair loss recurrence.

This review suggests that oral prednisolone pulse therapy and oral inosiplex may be effective for alopecia areata, but robust evidence from randomized controlled trials is lacking, highlighting the need for better-designed future studies.

This review discusses the potential of JAK inhibitors as a promising treatment strategy for alopecia areata, highlighting their mechanism and recent FDA approval based on clinical trial efficacy.

This study found that oral JAK inhibitors are effective and generally well-tolerated for treating alopecia areata, but high recurrence rates after stopping treatment suggest the need for continuous use.

This study found that vitamin D deficiency in patients with alopecia areata was associated with greater disease severity and longer duration, but not with disease pattern or vitamin D receptor expression.

This study reported that low-dose oral minoxidil is generally safe for treating various types of hair loss, though it may cause hypertrichosis and pedal edema, especially at higher doses.

This review discusses the use of topical and oral minoxidil for pediatric hair disorders, pointing out the lack of guidelines and the potential risks associated with systemic absorption, but reports no clinical results.

In this study, oral tofacitinib showed higher efficacy and tolerability in treating refractory alopecia totalis and universalis compared to traditional treatments, achieving a 50% improvement in severity scores for 44.4% of patients over six months, with fewer adverse effects.

This study found that dupilumab's effects on alopecia areata varied depending on patients' immune profiles, with Th2-skewed females seeing improvements and Th1-driven males experiencing worsening.

In this study, deuruxolitinib and baricitinib showed promising efficacy in treating alopecia areata, but effectiveness varied with dosage and further trials are needed to confirm these results.

This article provides new treatment guidelines for AA based on expert consensus while integrating regional healthcare variations, but it reports no new clinical results.

In this study, health state utility values revealed a significant impact on quality of life for patients with alopecia areata, particularly those with more extensive hair loss.

This review discusses the use of phosphodiesterase inhibitors for alopecia, finding promising preliminary results with topical caffeine for androgenetic alopecia and telogen effluvium, but limited success in alopecia areata.

This study found that in patients with alopecia areata, serum granulysin levels decreased significantly after treatment with tofacitinib and correlated with reduced disease severity, suggesting serum granulysin as an indicator of immunological activity and response to therapy.

This study reviews current treatments for alopecia areata, highlighting that despite various options like corticosteroids and immunosuppressives, their limited efficacy and potential side effects are challenges, while targeting specific cytokines has shown promise except with TNF inhibitors, which may worsen the condition.

This source reports that based on international Phase 3 trial results, the JAK1/2 inhibitor baricitinib was approved in Japan in June 2022 for treating extensive alopecia areata, offering a potentially useful treatment option.